A Nonintegrative Lentiviral Vector-Based Vaccine Provides Long-Term Sterile Protection against Malaria

Overview of attention for article published in PLOS ONE, November 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

twitter: 1 X user
patent: 9 patents

facebook: 1 Facebook page

Citations

dimensions_citation: 28 Dimensions

Readers on

mendeley: 50 Mendeley

Summary X Patents Facebook Dimensions citations

So far, Altmetric has seen 9 patents that reference this research output.

SARS-COV-2 IMMUNOGENIC COMPOSITIONS, VACCINES, AND METHODS

Application WO-2022167831-A1

World Intellectual Property Organisation (WIPO)

SARS-COV-2 IMMUNOGENIC COMPOSITIONS, VACCINES, AND METHODS

Application WO-2022013405-A1

World Intellectual Property Organisation (WIPO)

MALARIA PRE-ERYTHROCYTIC ANTIGENS AS A FUSION POLYPEPTIDE AND THEIR USE IN THE…

Application WO-2019224606-A1

World Intellectual Property Organisation (WIPO)

POLYMER-ENCAPSULATED VIRAL VECTORS FOR GENETIC THERAPY

Application WO-2019145796-A2

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity, including 5 additional patents.